Mr. Joel Shacker reports

CORE ONE'S AKOME REVEALS GROUNDBREAKING POSITIVE RESULTS FROM ITS SECOND ROUND OF STAGE 1 ANIMAL MODEL STUDIES FOR BIocOMPOUNDS TARGETING ALZHEIMER'S AND PARKINSON'S DISEASE

Core One Labs Inc. has received additional positive results from its second round of stage 1 animal model studies. The groundbreaking studies were conducted in collaboration with esteemed research partners at the Universitat de Barcelona, Spain, and were carried out on behalf of Core One's wholly owned subsidiary, Akome Biotechnologies Inc. These additional positive results come from the animal model studies that tested five carefully selected bioactive compounds based on their ability to mitigate, or eliminate disrupted physiological processes associated with a variety of neurological and mental health disorders, including Alzheimer's disease, Parkinson's disease, Ischemic stroke and depression. The fact that Akome is testing five compounds (biocompounds A to E) speaks to the company's diversified drug pipeline, which will allow Core One to potentially develop a number of different pharmaceuticals targeting a wide range of diseases, thereby increasing the company's revenue potential in the long term.

On July 24, 2023, Akome unveiled the initial findings from the first round of stage 1 animal model studies (round 1). These results showcased the potential of the plant bioactive compound referred to as biocompound A, the first among five biocompounds being investigated in the company's five United States Patent and Treaty Office applications. The data from this animal model demonstrated that biocompound A exhibits promising properties in significantly reducing motor dysfunction. This animal model motor dysfunction could be considered a proxy of the motor dysfunction observed in Parkinson's disease and prevalent in the late stages of Alzheimer's disease.

Building on this promising foundation, Core One's investigators have now received positive results for the remaining four biocompounds, namely biocompounds B through E, in the recently concluded round 2 stage 1 animal model studies. These studies were meticulously designed, following the exact testing criteria employed during round 1. The animal models were individually exposed to various concentrations of the respective biocompounds, and their motility was closely evaluated compared with a control sample of animal models not exposed to the biocompounds.

The data from round 2 studies for each of biocompounds B, C, D, and E demonstrated significant improvement in the animal models' motility when compared with the control sample. Additionally, investigators observed that as the dose concentration of the respective biocompounds increased, the improvement in the model's motility also increased, further underlining the significant potential therapeutic value of the patent-pending biocompounds.

Commenting on these achievements, Core One chief executive officer Joel Shacker stated: "I am incredibly excited about the positive results from all five of the biocompounds. Having all of our selected compounds perform so well creates massive potential for our drug development division, which is looking to create not just one, but multiple treatments that address global issues such as stroke, depression, Parkinson's and Alzheimer's. Increasing the amount of drugs that we develop could significantly increase our revenue in the future."

The combined significance of the previously reported round 1 and the current round 2 stage 1 animal model studies underscores the enormous promise of all five biocompounds currently under investigation.

As Core One continues its dedication to drug development and preclinical testing, these compounds stand as strong contenders for further evaluation and potential breakthroughs in treating motor dysfunction related to neurological disorders like Parkinson's and Alzheimer's.

About Core One Labs Inc.

Core One is a life science biotechnology research and development company focused on bringing psychedelic medicines to market through the development and production of psychedelic compounds, the advancement of psychedelic-assisted treatments, and the integration of novel delivery systems technology.

The company has a multifaceted business approach and incorporates several complementary lines of businesses and units in establishing itself as an industry leader in the rapidly growing and emerging psychedelic market space.

Core One, through its wholly owned subsidiary Vocan Biotechnologies Inc., has developed and filed for patent protection a proprietary psilocybin production system using engineered bacteria. It is also the holder of four provisional patents for the development of psychedelic-based pharmaceutical formulations targeting neurological and mental health disorders, under its 100-per-cent-owned subsidiary Akome Biotech Ltd., and three provisional patents under its other 100-per-cent-owned subsidiary, Awakened Biosciences Inc., for additional synthetic technologies for psilocybin and psilocin production methods.

In addition to the development of psychedelics and psychedelic compounds, Core One holds an interest in four medical clinics which maintain a combined database of more than 275,000 patients. Through its clinics, the company intends to integrate a rollout of its intellectual property related to psychedelic technologies and participate in the advancement of psychedelic-based treatments for mental health disorders.

We seek Safe Harbor.